Literature DB >> 23172731

Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis.

Zhuo Wu1, Osamu Matsui, Azusa Kitao, Kazuto Kozaka, Wataru Koda, Satoshi Kobayashi, Yasuji Ryu, Tetsuya Minami, Junichiro Sanada, Toshifumi Gabata.   

Abstract

PURPOSE: To evaluate the usefulness of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging (EOB-MRI) in differentiating between simple steatosis and nonalcoholic steatohepatitis (NASH), as compared with MR in-phase/out-of-phase imaging. The correlations between the MR features and histological characteristics were preliminarily investigated.
MATERIALS AND METHODS: From April 2008 to October 2011, 25 patients (13 simple steatosis and 12 NASH) who underwent both EOB-MRI and in-phase/out-of-phase imaging were analyzed. The hepatobiliary-phase enhancement ratio and signal intensity loss on opposed-phase T1-weighted images (fat fraction) were compared between the simple steatosis and NASH groups. In the simple steatosis and NASH groups, the correlations between enhancement ratio and histological grade/stage were explored. In the NASH group, fat fraction was correlated with the steatosis score.
RESULTS: The enhancement ratio in NASH was significantly lower than that in simple steatosis (P = 0.03). In the simple steatosis and NASH groups, the enhancement ratio was significantly correlated with the fibrosis stage (r = -0.469, P = 0.018). Fat fraction in NASH was strongly correlated with the steatosis score (r = 0.728, P = 0.007).
CONCLUSION: In simple steatosis and NASH, the hepatobiliary-phase enhancement ratio of EOB-MRI showed significant association with fibrosis stage, and may be a useful discriminating parameter compared with the fat fraction measured by in-phase/out-of-phase imaging.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23172731     DOI: 10.1002/jmri.23921

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  [Techniques for quantification of liver fat in risk stratification of diabetics].

Authors:  J-P Kühn; M C Spoerl; C Mahlke; K Hegenscheid
Journal:  Radiologe       Date:  2015-04       Impact factor: 0.635

2.  Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.

Authors:  Ying Ding; Sheng-Xiang Rao; Tao Meng; Caizhong Chen; Renchen Li; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2014-01-26       Impact factor: 5.315

Review 3.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

4.  Hyperintensity at fat spared area in steatotic liver on the hepatobiliary phase MRI.

Authors:  Emre Ünal; İlkay Sedakat İdilman; Ali Devrim Karaosmanoğlu; Mustafa Nasuh Özmen; Deniz Akata; Muşturay Karcaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2019-11       Impact factor: 2.630

5.  Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yoshiki Asayama; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Ken Shirabe; Tomoharu Yoshizumi; Kazuhiro Kotoh; Norihiro Furusyo; Tomoyuki Hida; Yoshinao Oda; Taisuke Fujioka; Hiroshi Honda
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

6.  Influence of hepatic fibrosis and inflammation: Correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging.

Authors:  N Verloh; U Probst; K Utpatel; F Zeman; F Brennfleck; J M Werner; C Fellner; C Stroszczynski; M Evert; P Wiggermann; M Haimerl
Journal:  PLoS One       Date:  2019-05-13       Impact factor: 3.240

Review 7.  Quantification of liver function using gadoxetic acid-enhanced MRI.

Authors:  Sarah Poetter-Lang; Nina Bastati; Alina Messner; Antonia Kristic; Alexander Herold; Jacqueline C Hodge; Ahmed Ba-Ssalamah
Journal:  Abdom Radiol (NY)       Date:  2020-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.